<DOC>
	<DOC>NCT02255045</DOC>
	<brief_summary>The investigators propose that the sustained vaginal administration would have a better response with respect to pain, and a better safety profile than the oral administration of a non-steroidal anti-inflammatory drug. Assess the relief of the symptoms associated to dysmenorrhea a specific survey was elaborated that also included a Visual Analog Scale (VAS) to make objective and measure dysmenorrhea as is the case with McGill's Pain Questionnaire (MPQ).</brief_summary>
	<brief_title>Assess of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Regular menstrual cycles on previous 3 months (2435 days), Primary dysmenorrhea on 3 previous months, With tubal ligation or users of condom for contraception, Hemoglobin of at least 11 g/dl, Safety blood analysis in normal levels Secondary dysmenorrhea, Users of hormonal contraceptives (2 months prior to the study) or IUDs (intrauterine devices) (1 month prior the study). Allergy to any anti inflammatory drug including meloxicam or diclofenac. Allergy to silicon. Pregnant or in lactation. Women with untreated or decompensated endocrine disorders</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>